Found: 29
Select item for more details and to access through your institution.
Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Comparison of two regimens of weekly paclitaxel plus gemcitabine in patients with metastatic breast cancer: propensity score–matched analysis of real-world data.
- Published in:
- Therapeutic Advances in Drug Safety, 2022, v. 13, p. 1, doi. 10.1177/20420986221146411
- By:
- Publication type:
- Article
Cuproptosis-related risk score predicts prognosis and characterizes the tumor microenvironment in colon adenocarcinoma.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1152681
- By:
- Publication type:
- Article
Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.1056932
- By:
- Publication type:
- Article
ER status conversion and subsequent treatment: an assessment of negative ER expression detected by 18F-FES PET in metastatic breast cancer patients with ER-positive primary tumors.
- Published in:
- Therapeutic Advances in Medical Oncology, 2023, p. 1, doi. 10.1177/17588359231216093
- By:
- Publication type:
- Article
Real-world data of triplet combination of pyrotinib, trastuzumab, and chemotherapy in HER2-positive metastatic breast cancer: a multicenter, retrospective study.
- Published in:
- Therapeutic Advances in Medical Oncology, 2023, p. 1, doi. 10.1177/17588359231217972
- By:
- Publication type:
- Article
Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study.
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/17588359211030210
- By:
- Publication type:
- Article
Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study.
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/17588359211030210
- By:
- Publication type:
- Article
Clinicopathological characteristics, evolution, treatment pattern and outcomes of hormone-receptor-positive/HER2-low metastatic breast cancer.
- Published in:
- Frontiers in Endocrinology, 2023, p. 1, doi. 10.3389/fendo.2023.1270453
- By:
- Publication type:
- Article
Chromatin Remodelling Molecule ARID1A Determines Metastatic Heterogeneity in Triple-Negative Breast Cancer by Competitively Binding to YAP.
- Published in:
- Cancers, 2023, v. 15, n. 9, p. 2447, doi. 10.3390/cancers15092447
- By:
- Publication type:
- Article
Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of 18 F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer.
- Published in:
- Cancers, 2022, v. 14, n. 16, p. 3973, doi. 10.3390/cancers14163973
- By:
- Publication type:
- Article
Chemotherapy Shows a Better Efficacy Than Endocrine Therapy in Metastatic Breast Cancer Patients with a Heterogeneous Estrogen Receptor Expression Assessed by 18 F-FES PET.
- Published in:
- Cancers, 2022, v. 14, n. 14, p. N.PAG, doi. 10.3390/cancers14143531
- By:
- Publication type:
- Article
Heterogeneity derived from <sup>18</sup>F‐FDG PET/CT predicts immunotherapy outcome for metastatic triple‐negative breast cancer patients.
- Published in:
- Cancer Medicine, 2022, v. 11, n. 9, p. 1948, doi. 10.1002/cam4.4522
- By:
- Publication type:
- Article
Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real‐world study for patients with hormone receptor‐positive and HER2‐negative advanced breast cancer.
- Published in:
- Cancer Medicine, 2020, v. 9, n. 23, p. 8821, doi. 10.1002/cam4.3491
- By:
- Publication type:
- Article
Real‐world data of lapatinib and treatment after lapatinib in patients with previously treated HER2‐positive metastatic breast cancer: A multicenter, retrospective study.
- Published in:
- Cancer Medicine, 2020, v. 9, n. 9, p. 2981, doi. 10.1002/cam4.2943
- By:
- Publication type:
- Article
Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Retrospective Study.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.699333
- By:
- Publication type:
- Article
Pretreatment <sup>18</sup>F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer.
- Published in:
- Cancer Imaging, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s40644-023-00608-0
- By:
- Publication type:
- Article
Phase II trial of nab-paclitaxel in metastatic breast cancer patients with visceral metastases.
- Published in:
- BMC Cancer, 2021, v. 21, n. 1, p. 1, doi. 10.1186/s12885-021-08921-2
- By:
- Publication type:
- Article
Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer.
- Published in:
- International Journal of General Medicine, 2021, v. 14, p. 1797, doi. 10.2147/IJGM.S293998
- By:
- Publication type:
- Article
Heterogeneity of targeted lung lesion predicts platinum-based first-line therapy outcomes and overall survival for metastatic triple-negative breast cancer patients with lung metastasis: a "PET biopsy" method.
- Published in:
- Cancer Management & Research, 2019, v. 11, p. 6019, doi. 10.2147/CMAR.S204364
- By:
- Publication type:
- Article
Everolimus‐Related Pneumonitis in Patients with Metastatic Breast Cancer: Incidence, Radiographic Patterns, and Relevance to Clinical Outcome.
- Published in:
- Oncologist, 2021, v. 26, n. 4, p. e580, doi. 10.1002/onco.13594
- By:
- Publication type:
- Article
Pretreatment <sup>18</sup>F‐FDG Uptake Heterogeneity Predicts Treatment Outcome of First‐Line Chemotherapy in Patients with Metastatic Triple‐Negative Breast Cancer.
- Published in:
- Oncologist, 2018, v. 23, n. 10, p. 1144, doi. 10.1634/theoncologist.2018-0001
- By:
- Publication type:
- Article
Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. 1, doi. 10.1038/s41598-019-39314-y
- By:
- Publication type:
- Article
Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. 1, doi. 10.1038/s41598-018-37472-z
- By:
- Publication type:
- Article
Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study.
- Published in:
- Scientific Reports, 2018, v. 8, n. 1, p. 1, doi. 10.1038/s41598-018-32745-z
- By:
- Publication type:
- Article
Mammary adipocytes protect triple-negative breast cancer cells from ferroptosis.
- Published in:
- Journal of Hematology & Oncology, 2022, v. 15, n. 1, p. 1, doi. 10.1186/s13045-022-01297-1
- By:
- Publication type:
- Article
Mammary adipocytes protect triple-negative breast cancer cells from ferroptosis.
- Published in:
- 2022
- By:
- Publication type:
- Letter
Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience.
- Published in:
- 2020
- By:
- Publication type:
- journal article